Physician profile
Keith Bersch
NPI 1598141921
$1,578.26
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $958 · 2022: $621.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $445.56 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $256.88 | 2021-2022 | |
| Janssen Biotech, INC. | $249.18 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $151.45 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $90.80 | 2021 | |
| Abbvie INC. | $85.90 | 2022 | |
| Redhill Biopharma INC. | $85.04 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $74.34 | 2022 | |
| Vivus LLC | $36.08 | 2022 | |
| Ardelyx, INC. | $35.80 | 2022 | |
| Braintree Laboratories, INC. | $21.56 | 2021 | |
| Daiichi Sankyo INC. | $19.26 | 2022 | |
| Ferring Pharmaceuticals INC. | $14.76 | 2021 | |
| Qol Medical, LLC | $11.65 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Bersch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.